CD8A and melanoma: IL2-sEVs increased the anti-cancer ability of CD8+ T cells without affecting Treg and down-regulated cellular and exosomal PD-L1 expression in melanoma cells, causing their increased sensitivity to CD8+ T cell-mediated cytotoxicity.